Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (February 2018)

Monday, March 26, 2018

Between January and February 2018, Russian manufacturers dispatched 46.9 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 1.3% lower than that of the same period of 2017. In physical terms, Russia produced nearly 670 units of drugs, which is 4.9% lower than that of the same period of 2017. The production of over-the-counter drugs has fallen by 9.5%, while the Rx category has a 3.8% growth.

Despite the pessimistic results of the first two months combined, the February results seem a bit better than the January ones. In February 2018, Russia produced 24.9 bln RUB worth of drugs (dispatch prices, VAT included), which is in monetary terms 0.7% higher than that of February 2017 and 4.2% lower in physical terms (against -5.7% in January 2018.)

Between January and February 2018, Pharmstandard and Tatkhimfarmpreparaty witnessed the biggest fall in sales, with -24% and -19%. Out of the top 20 companies, Promomed and Slavyanskaya Apteka made the best progress, with a 3.7 and 3.6 times growth. For Promomed, the product that contributed to the success is Ceftriaxonum, with its production having increased by nearly 100 times over the year. For Slavyanskaya Apteka, this product is Naftizin, with its production having increased by 3.9 times over the year.

Read more about pharmaceutical drug production in Russia (January results) here: http://rncph.com/news/01_03_2018

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – February 2018)

Share: